esrakarabag.dr@hotmail.com
2Ruveyda Gulmez, akerruveyda@gmail.com
2Nur Canpolat, ncanpolat2000@hotmail.com
1Ayca Kiykim, ayca.kiykim@iuc.edu.tr
1Haluk Cezmi Cokugras, cokugras@gmail.com
1Istanbul University-Cerrahpasa, Department of
Pediatric Immunology and Allergy, Istanbul
2Istanbul University-Cerrahpasa, Department of
Pediatric Nephrology, Istanbul
- Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the
KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney
Int 100:753–779.
- Ataca P, Atilla E, Kendir R, Bavbek S, Ozcan M. Successful
desensitization of a patient with rituximab hypersensitivity. Case
Reports Immunol. 2015;2015:524507.
- D. I. Hong, L. Bankova, K. N. Cahill, T. Kyin, and M. C. Castells.
Allergy to monoclonal antibodies: cutting-edge desensitization methods
for cutting-edge therapies. Expert Review of Clinical Immunology, vol.
8, no. 1, pp. 43–54, 2012.
- Pichler WJ, Hausmann O. Classification of drug hypersensitivity into
allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol
2016; 171:166 – 179.
- Bumbacea RS, Ali S, Corcea SL, Spiru L, Nitipir C, Strambu V, Bumbacea
D. Omalizumab for successful chemotherapy desensitisation: What we
know so far. Clin Transl Allergy. 2021 Dec 13;11(10):e12086.
- Taha R, El-Haddad H, Almuallim A, Alshaiki F, Obaid E, Almoallim H.
Systematic review of the role of rituximab in treatment of
antineutrophil cytoplasmic autoantibody-associated vasculitis,
hepatitis C virus-related cryoglobulinemic vasculitis,
Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud’s
phenomenon. Open Access Rheumatol 2017;9:201-14.
- Görgülü B, Seval GC, Kendirlinan R, Toprak SK, Özcan M, Bavbek S.
Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center
Experience. J Investig Allergol Clin Immunol. 2019;29(6):468-470.
- Isabwe GAC, Neuer MG, de las Vecillas Sanchez L, Lynch DM, Marquis K,
Castells M. Hypersensitivity reactions to therapeutic monoclonal
antibodies: phenotypes and endotypes. J Allergy Clin Immunol.
2018;142(1):159-71
- Fernandez J, Ruano-Zaragoza M, Blanca-Lopez N. Omalizumab and other
biologics in drug desensitization. Curr Opin Allergy Clin Immunol.
2020 Aug;20(4):333-337.
- Arroabarren E, Aznal E, Anda M, Sanchez-Valverde F. Anaphylaxis after
Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement
therapy desensitization. Pediatr Allergy Immunol. 2019
Jun;30(4):491-494.